Invention Grant
- Patent Title: BChE albumin fusions for the treatment of cocaine abuse
- Patent Title (中): BChE白蛋白融合治疗可卡因滥用
-
Application No.: US12962410Application Date: 2010-12-07
-
Publication No.: US08541373B2Publication Date: 2013-09-24
- Inventor: Liora Sklair-Tavron , Moti Rosenstock , Liron Shemesh-Darvish , Hussein Hallak , Victor Piryatinsky , Viktor Roschke , David Lafleur
- Applicant: Liora Sklair-Tavron , Moti Rosenstock , Liron Shemesh-Darvish , Hussein Hallak , Victor Piryatinsky , Viktor Roschke , David Lafleur
- Applicant Address: IL Petach-Tikva
- Assignee: Teva Pharmaceutical Industries Ltd.
- Current Assignee: Teva Pharmaceutical Industries Ltd.
- Current Assignee Address: IL Petach-Tikva
- Agency: Cooper & Dunham LLP
- Agent John P. White; Gary J. Gershik
- Main IPC: A61P25/36
- IPC: A61P25/36
Abstract:
A method of attenuating a biological effect of cocaine exposure in a primate. Such method includes administering to the primate an amount of a BChE-albumin fusion protein comprising the amino acid substitutions A227S, S315G, A356W, and Y360G, wherein the amount of the fusion protein is effective to cause attenuation of the biological effect of cocaine exposure in the primate.
Public/Granted literature
- US20110312900A1 BChE ALBUMIN FUSIONS FOR THE TREATMENT OF COCAINE ABUSE Public/Granted day:2011-12-22
Information query
